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Abstract: The design and the preparation of a small library of 1,4-diphenyl-1,2,3-
triazole derivatives is reported, with the aim to obtain a new class of Hedgehog 
pathway inhibitors. The smoothened (SMO) protein is part of the hedgehog signalling 
pathway that is inhibited by the lead compound Vismodegib. Based on molecular 
modeling suggestions, seven triazole derivatives of Vismodegib were synthesized and 
their biological effect on different endothelial, cancer and cancer stem cell lines is 
reported.  
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1. Introduction 
Vismodegib1 is a synthetic Smoothened (SMO) antagonist that inhibits the Hedgehog 
(Hh) signaling pathway,2 by preventing SMO translocation to the primary cilium. 
Acquired resistance to Vismodegib, due to smoothened mutations during the 
treatment of locally advanced basal cell carcinoma, has been reported recently.3 The 
design of new scaffolds for the discovery of novel Hh inhibitors4 is a current goal that 
could help to face the problem of cancer stem cells5 whose behavior depends also on 
the Hedgehog pathway.6 Therefore, we considered the modification of the 
Vismodegib scaffold to look for an improvement of its performance or to further 
explore its pharmacophoric properties.  
Based on our previous results,7, 8 we focused our attention on the substitution of the 
amide bond present in the Vismodegib structure with a 1,2,3-triazole ring. The 
bioisosterism between the amide group and 1,2,3-triazole ring is well known9 and 
further supported herein by docking simulations. In this paper we report the rational 
design, versatile synthesis and biological evaluation of triazole-based Vismodegib 
analogues. 
 
 
Figure 1. General structure of designed Vismodegib analogues. 
 
2. Results and Discussion 
 
2.1. Molecular Modeling 
A small virtual library of 140 triazole derivatives was built in silico as previously 
reported, based on the synthetic feasibility of the compounds and accounting for a 
number of simple and pharmacophoric substituents.10  
To monitor whether amide replacement with triazole in Vismodegib scaffold may 
impact SMO binding, the virtual library of triazole derivatives and Vismodegib were 
docked within the antagonist site at the extracellular end of the SMO heptahelical 
bundle. To this aim, the crystallographic structure of SMO in complex with a small 
molecule antagonist (PDB ID: 4JKV)11 was used as rigid receptor in molecular 
docking simulations, which were performed with the HYBRID program from 
OpenEye (see Materials and Methods for computational details).12, 13 Due to the lack 
of benchmarking studies on the performance of docking and scoring functions to the 
SMO receptor, theoretical affinity was herein computed by the Chemgauss4 and the 
XSCORE functions.14 
Based on results obtained by docking the virtual library, seven triazoles (1-7, Scheme 
1) were synthesized as described in Scheme 1 and tested in vitro. 
 
2.2. Chemistry 
The synthesis of the final compounds 1 - 7 was accomplished according to the general 
synthetic strategy based on a 1,3-dipolar cycloaddition and reported in Scheme 1. The 
preparation of the proper building blocks is described in Scheme 2 (azides) and 
Scheme 3 (alkynes). A Suzuki coupling reaction of 4-tert-butylphenylboronic acid 
(Scheme 2) with 1-chloro-2-iodo-4-nitrobenzene (9) or the commercially available 1-
iodo-3-nitrobenzene (10) provided the intermediates 11 and 12 in excellent yields. 
Continuously, reduction of the nitro group, with hydrazine monohydrate/iron(III) 
chloride in the presence of active carbon gave the amines 13 and 14, which were then 
transformed to the azide derivatives 15 and 16 by the formation of diazonium salt and 
subsequent reaction with a solution of sodium azide in water. Sharpless cycloaddition8 
of azides 15 and 16 with alkynes 29 and the commercially available methyl 4-
ethynylbenzoate furnished the desired products 1 and 2 respectively (65-75 % yield). 
Reduction of compound 2 with LiAlH4 afforded the desired derivative 6.  
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Scheme 1. Reagents and conditions: (a) Corresponding azides and alkynes, sodium ascorbate, 
CuSO4·5H2O, t-BuOH:H2O (1:1), reflux, 3 h; (b) LiAlH4, THF, 0 ºC to rt, 1 h. 
 
Synthesis of the compound 3 was accomplished in a two-step sequence: the 
commercially available amine 24 was transformed to azide 25 and then submitted to a 
Sharpless cycloaddition with methyl 4-ethynylbenzoate to give the desired compound 
3. Afterwards, reduction of compound 3 with LiAlH4 provided the desired derivative 
7.  
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Scheme 2. Reagents and conditions: (a) NaNO2, KI, H2SO4, H2O, 0 ºC to rt, 1 h; (b) 4-tert-
Butylphenylboronic acid, Pd(OAc)2, K2CO3, MeOH:H2O (5:1), reflux, 4 h (c) N2H4·H2O, FeCl3, active 
C, MeOH, reflux, 2 h; (d) 1-Iodo-3-nitrobenzene or compound 9, PPh3, Pd(PPh3)4, DMA, THF, 60 ºC; 
(e) NaNO2, NaN3, CH3COOH:H2O (1:1), 0 ºC to rt, 2 h. 
 
For the synthesis of analogues 4 and 5 the commercially available 2-pyridylzinc 
bromide (17) was used for the construction of the phenylpyridine moiety. Negishi 
coupling between compound 17 and 1-iodo-3-nitrobenzene or compound 9 gave the 
corresponding nitro compounds 18 and 19. Then, reduction of the nitro group, with 
hydrazine monohydrate/iron(III) chloride in the presence of active carbon gave the 
amines 20 and 21, which were then transformed to the azide derivatives 22 and 23 by 
the formation of diazonium salt and subsequent reaction with a solution of sodium 
azide in water. Sharpless cycloaddition between azide 22 and alkyne 32 (Scheme 3) or 
azide 23 and alkyne 29 (Scheme 3) provided the desired products 4 and 5 
respectively. 
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Scheme 3. Reagents and conditions: (a) LiAlH4, THF, 0 ºC to rt, 1 h; (b) Dess-Martin periodinane, 
DCM, rt, 2 h; (c) Bestmann-Ohira reagent, K2CO3, MeOH, 0 ºC to rt, 3 h; (d) Trimethylsilylacetylene, 
CuI, PdCl2(PPh3)4, DCM:Et3N (1:1), rt; (e) TBAF, THF, rt, 1 h. 
 
2.3. Biological Evaluation 
We first evaluated the inhibitory effect of selected compounds 1-7 on the 
proliferation of three cancer cell lines [murine leukemia cells (L1210), human T-
lymphocyte cells (CEM) and human cervix carcinoma cells (HeLa)] and  two 
endothelial cell lines [human microvascular endothelial cells (HMEC-1) and bovine 
aortic endothelial cells (BAEC)]. Data are expressed as IC50 (50% inhibitory 
concentration), defined as the concentration at which the compounds reduce cell 
proliferation by 50% and are shown in Table 1.  
Compounds 2 and 4 showed poor activity against tumor cell lines with 50% 
inhibitory values higher than 100 µM. A modest anti-proliferative activity was 
observed for compounds 1, 5 and 7, with IC50 values ≥ 50 µM against the different 
tumor cell lines. However, these compounds inhibited the proliferation of human 
microvascular endothelial HMEC-1 cells with IC50 values between 10 and 14 µM. 
Compound 6 proved active in the lower micromolar range in all cell lines tested. The 
most active compound 3 inhibited tumor and endothelial cell proliferation with IC50 
values ≤ 1 µM. Thus, although the compounds significantly differ in their inhibitory 
activity against different tumor cell lines, they all show pronounced antiproliferative 
activity against human microvascular endothelial cells. 
 
Table 1. Inhibitory effects of the compounds on cell proliferation (IC50, µM) 
 L1210 CEM HeLa BAEC HMEC-1 
1 80 ± 29 > 100 57 ± 4 >100 5.6 ± 1.3 
2 > 100 > 100 > 100 >100 6.9 ± 4.8 
3 1.1 ± 0.0 0.92 ± 0.01 1.1 ± 0.3 0.42 ± 0.04 0.62 ± 0.11 
4 > 100 > 100 > 100 > 100 11 ± 1 
5 82 ± 72 50 ± 12 > 100 40 ± 10 9.6 ± 0.7 
6 10 ± 0 12 ± 1 13 ± 2 7.1 ± 1.5 7.0 ± 1.3 
7 95 ± 12 64 ± 4 72 ± 7 >100 11 ± 11 
GDC-0499 49 ± 9 58 ± 6 64 ± 4 50 ± 4 41 ± 3 
 
The compounds were also tested for their cytotoxic activity on ovarian cancer cell line 
(OVCAR5) and two ovarian cancer stem cells (#83, #110), recently isolated.15 Figure 
2 reports the dose-response curve in the three different systems for both Vismodegib 
(left panel) and compound 4. Similarly to the data observed for the other cell lines, the 
cytotoxic activity of the compounds was poor but similar in all the three systems used. 
Figure 2. Dose response curves of vismodegib and compound 4 in #83, #110 and OVCAR5 cell lines. 
Data are expressed as % of controls and are the mean of two experiments done in sixplicates. 
 
Glioblastoma is the most common and lethal primary brain tumour. Despite surgical 
removal and aggressive chemo/radiotherapy, its prognosis remains hitherto very poor. 
Hedgehog signalling plays a central role in glioblastoma development and 
progression.16 For this reason, we used two glioblastoma cell lines, U251 and SF268, 
in order to evaluate the efficacy of the described compounds against this type of 
cancer. To this end, we cultured U251 and SF268 cells until semi-confluent and then 
added the described compounds at 25 μM. Cells were collected after 48h. BrdU was 
added in the medium at 0.4 mg/ml for the last 1 hour. As illustrated in Figure 3a, the 
compounds 2–7 significantly reduced cell proliferation (from 20 to 83%), although 
only compounds 3 and 6 at the levels of Vismodegib. The effect was similar in both 
cell lines, but more pronounced in U251 cells. We also estimated the effect of the 
compounds on cell death, and we analysed by flow cytometry apoptosis, using active 
caspase-3 immunofluorescence. Vismodegib and compound 3 induced cell death in 
both cell lines, while compounds 1, 6 and 7 induced low levels of apoptosis mainly in 
U251 cells (Figure 3b). We then selected the compounds that showed significant 
effect in terms of both proliferation and apoptosis, and the U251 cell line that proved 
more sensitive, and assessed the dose response of those cells to compound 
concentrations from 1 to 50 μΜ (Figure 3c, d). Our results showed a clear dose-
dependent response for both proliferation inhibition and apoptosis against all the 
compounds tested, with compound 3 and Vismodegib having the more prominent and 
very similar effect. 
Figure 3. a. Effect of the described compounds on the proliferation of U251 and SF268 glioblastoma 
cell lines, at a concentration of 25μM after 48h of culture, as estimated by BrdU incorporation and 
analysis by flow cytometry. Results are presented as fold over the proliferation of control cultures 
where only the vehicle was added. b. Effect of the described compounds on apoptosis of U251 and 
SF268 cells, at a concentration of 25μM after 48h of culture, as estimated by flow cytometry detecting 
active Caspase-3 expression. c, d. Dose response curves of the effect of Vismodegib, 3, 6 and 7 on the 
proliferation (c) and apoptosis (d) of U251 cells, after 48h of culture. Mean of 3 independent 
experiments is shown. Values are expressed as mean±SD. 
 
Given the cell cycle arrest shown by the BrdU-incorporation analysis, we sought to 
investigate whether there is a specific checkpoint activated by the different 
compounds. We thus performed cell cycle analysis, using propidium iodide. 
Interestingly, U251 cells exposed to Vismodegib or compound 3 (Figure 4) 
accumulate in the S phase of the cell cycle. However, this does not reflect higher 
proliferation of those cells, since the BrdU incorporation assay clearly showed that 
these two compounds severely impaired cell proliferation. Consequently, we can 
assume that exposure to Vismodegib or compound 3 activates an intra-S checkpoint in 
those cells. 
 
 
Figure 4. Effect of the described compounds on the cell cycle of U251 cells, at a concentration of 
25μM after 48h of culture, as estimated by flow cytometry using Propidium Iodide. Apoptotic and 
aneuploid cells have been excluded. Mean of 3 independent experiments is shown. Values are 
expressed as mean±SD. 
 
In order to investigate whether the effect of the compounds tested is indeed mediated 
by inhibition of the Hedgehog pathway, we performed transcriptional analysis by 
quantitative RT-PCR for the main genes of the Hh pathway, Gli1, Gli2 and Ptch1. 
Surprisingly, while Vismodegib addition did result in significant reduction of the 
transcriptional levels of all 3 genes tested, compound 3 did not have a significant 
effect in Hh pathway, showing that this compound mediates proliferation inhibition 
and cell death via another mechanism that would be interesting to be tested in the 
future. In contrast, compound 6, although having a milder effect on proliferation and 
apoptosis in the cell lines tested, mediated this effect, at least partly, via Hh pathway 
inhibition (Figure 5). 
 
Figure 5. Transcriptional analysis of components of the Hedgehog signaling pathway as estimated by 
quantitative RT-PCR, 24h upon addition of the described compounds at 25μM. Results are expressed 
as fold change over the mRNA expression in the control cultures, where only the vehicle was added. 
Mean of 3 independent experiments is shown.  Values are expressed as mean±SD. 
 
The activity of compound 3 against endothelial cells moved us to evaluate its effect 
on endothelial cell migration and tube formation, two important processes involved in 
the formation of new blood vessels. Compound 3 did not inhibit endothelial cell 
migration (not shown), but a dose-dependent inhibition of tube formation was 
observed (Figure 6).  
 
     
Figure 6. Effect of compound 3 on angiogenesis. HMEC-1 cells were seeded on matrigel in the 
presence of different concentrations (100 – 20 – 4 µM) of compound 3. After 3 h of incubation, 
endothelial cell tubes were photographed and scored. Average and S.E.M (n=4) are shown.*p<0.05. 
 
 
3. Conclusions 
The preparation of seven 1,4-diphenyl-1,2,3-triazole derivatives has been described 
by Huisgen cycloaddition. Molecular modeling results suggest the replacement of the 
amide moiety of Vismodegib with triazole group as a possibility for further structure-
based optimization studies. The biological evaluation on different types of cell lines 
showed interesting activity of compounds 3 and 6 against cancer and endothelial cells. 
Compound 3 showed interesting activity on glioblastoma cells and seems to block 
cells in S phase similarly to Vismodegib. Transcriptional analysis by quantitative RP-
PCR for the main genes of the Hh pathway, Gli1, Gli2 and Ptch1 confirmed 
compound 6 as able to interact with Hh pathway and suggested a different mechanism 
for compound 3 to justify its ability to inhibit proliferation. Moreover, compound 3 
proved to be a potential inhibitor of the formation of blood vessels. To sum up, all the 
reported results point out the subsequent: a) 1,4-diphenyl-1,2,3-triazole framework as 
a good scaffold for the generation of new promising compounds and b) the use of 
1,2,3-triazole system as a useful way to connect pharmacophores. 
 
4. Experimental 
4.1. General procedures  (see Supporting Information) 
 
4.2. Synthesis (see Supporting Information) 
 
4.3. Molecular modeling 
The tridimensional structure of SMO in complex with a small molecule antagonist 
was downloaded from the Protein Data Bank (www.rcsb.org/pdb; PDB accession 
code: 4JKV).11 Co-crystalized ligands and water molecules were manually removed, 
and the receptor was prepared for docking with the make_receptor utility of the 
OEDocking software from OpenEye.12, 13 Ligand conformational analysis was 
performed with the software OMEGA, which generated up to 600 conformers for 
each ligand.17-19 Molecular docking was performed with HYBRID from OpenEye,12, 
13 using the “High” docking resolution flag and all other default options, while 
rescoring was performed by means of the XSCORE function.14 
 
4.4. Biological evaluation  
 
4.4.1. Cell lines.  
Endothelial cells: Bovine aortic endothelial cells (BAEC) and human dermal 
microvascular endothelial cells (HMEC-1) were seeded in 48-well plates at 10,000 
cells/well and 20,000/well, respectively. After 24 h, 5-fold dilutions of the compounds 
were added. The cells were allowed to proliferate 3 days (or 4 days for HMEC-1) in 
the presence of the compounds, trypsinized, and counted by means of a Coulter 
counter (Analis, Belgium). 
Tumor cells: Human cervical carcinoma (HeLa) cells were seeded in 96-well plates at 
15,000 cells/well in the presence of different concentrations of the compounds. After 
4 days of incubation, the cells were trypsinized and counted in a Coulter counter. 
Suspension cells (Mouse leukemia L1210 and human lymphoid Cem cells) were 
seeded in 96-well plates at 60,000 cells/well in the presence of different 
concentrations of the compounds. L1210 and Cem cells were allowed to proliferate 
for 48 h or 96 h, respectively and then counted in a Coulter counter. The 50% 
inhibitory concentration (IC50) was defined as the compound concentration required to 
reduce cell proliferation by 50%.  
The glioblastoma cell line U251 (ECACC) was cultured in EMEM, supplemented 
with 2mM Glutamine, 1% Non Essential Amino Acids, 1mM Sodium Pyruvate and 
10% Foetal Bovine Serum (all by Life Technologies). Glioblastoma SF268 cells were 
cultured in RPMI (Life Technologies), supplemented with 2mM Glutamine and 10% 
Foetal Bovine Serum.  
#83 and #110 cell lines were obtained and maintained as already reported.15 Briefly 
they were maintained in low adherence flasks (Corning) under stem-cell conditions: 
serum-free DMEM/F12 supplemented with 5 µg/mL insulin (Sigma), 20 ng/mL 
human recombinant epidermal growth factor (EGF, Peprotech), 10 ng/mL basic 
fibroblastic growth factor (bFGF, Peprotech) and B27 Supplement (Gibco). For 
cytotoxic experiments, Ovcar5 and #83 and #110 cells derived from dissociated 
spheres were plated in 96 well plates at a concentration of 12500 cells/mL. 96 hours 
later cells were treated with different drugs doses. Cell survival was assessed at 72 h 
by MTS assay and dose-response curves were plotted. 
 
4.4.2. Tube formation assay.  
Wells of a 96-well plate were coated with 70 µl matrigel (10 mg/ml, BD Biosciences, 
Heidelberg, Germany) at 4°C. After gelatinization at 37°C during 30 min, HMEC-1 
cells were seeded at 60,000 cells/well on top of the matrigel in 200 µl DMEM 
containing 10% FCS and the test compounds. After 3 hours of incubation, the cell 
structures were photographed and scored. A two-tailed unpaired Student’s t-test was 
used to assess the significance of the obtained results. 
 
4.4.3. Flow cytometry.  
BrdU was detected using the BrdU Flow Kit and anti-BrdU conjugated with FITC (at 
1/50). Active caspase-3 was detected using PE-conjugated anti-active Caspase 3 
antibody (1/25) and BD Perm/Wash reagent (all by BD Biosciences). Cell cycle 
analysis was performed using propidium iodide. Briefly, cells were permeabilised 
with ethanol on ice and stained for 40 min at 37oC with 50 μg/ml propidium iodide in 
the presence of 0.1 mg/ml RNase A and 0.05% Triton X-100 (all from Sigma-
Aldrich). FACS analysis was performed using LSR Fortessa and FACS DiVa 
software (BD Biosciences). 
 
4.4.4. Reverse transcription and quantitative RT-PCR.  
RNA extraction was performed using Absolutely RNA Microprep kit (Stratagene). 1 
µg of purified RNA was used to synthesize the first strand cDNA in a final volume of 
50 µl, using a Superscript II (Invitrogen) and random hexamers (Roche). qPCR 
analyses were performed with one-hundredth of the cDNA reaction as template, using 
a Quantifast SYBR Green mix (Qiagen) on an Agilent Technologies Stratagene 
Mx3500P real-time PCR system. Hypoxanthine phosphoribosyltransferase (HPRT) 
and βeta-actin were used as housekeeping internal reference genes. All primers were 
designed to amplify amplicons in the intron-exon junctions. Specificity of the PCR 
amplification was assessed by electrophoresis of the amplicons on 2% agarose gels.  
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